CompletedNot Applicable

Intermittent vs Continuous Enteral Nutrition in Glycaemic Control of Diabetic ICU Patients

Turkey (Türkiye)25 participantsStarted 2023-12-02

Plain-language summary

The goal of this clinical trial is to learn if intermittent or continuous enteral nutrition applications can improve glycemic control and affect certain metabolic parameters in adult critically ill patients with diabetes receiving clinical nutrition therapy. The main questions it aims to answer are: Does intermittent enteral nutrition lead to better glycemic control compared to continuous enteral nutrition? How do intermittent and continuous enteral nutrition applications affect metabolic parameters such as serum insulin levels, lipid profile, and inflammatory markers? Researchers will compare intermittent and continuous enteral nutrition groups to see if one method is more effective in improving glycemic control and metabolic outcomes. Participants will: Receive either intermittent or continuous enteral nutrition as part of their clinical nutrition therapy Have regular blood tests to monitor blood glucose, insulin, lipid profile, and inflammatory markers Be monitored for glycemic variability and metabolic changes during their ICU stay

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 or older Diagnosis of diabetes Receiving enteral nutrition Indication for at least 7 days of ICU admission to perform the study Exclusion Criteria: * Under 18 years old Having specific needs that would require a completely different type of treatment, such as cancer or cystic fibrosis Pregnancy Expected to stay in the ICU for less than 7 days Receiving oral feeding or TPN (Total Parenteral Nutrition)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Blood Glucose Levels (mg/dL)

Timeframe: Five measurements per day at 06:00, 11:00, 16:00, 21:00, and 01:00, for 7 consecutive days

Trial details

NCT IDNCT07054476

SponsorHacettepe University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-16

View on ClinicalTrials.gov More Diabetes Mellitus trials